Literature DB >> 7989484

Source localization of androgen excess in adolescent girls.

L Ibáñez1, N Potau, M Zampolli, N Prat, M Gussinyé, P Saenger, E Vicens-Calvet, A Carrascosa.   

Abstract

Functional ovarian hyperandrogenism (FOH) is characterized by an abnormal ovarian response to challenge with the GnRH analogs nafarelin and leuprolide acetate, similar to that observed in women with well defined polycystic ovary syndrome, regardless of whether elevated LH levels or polycystic ovaries are present. We studied an unselected group of 42 hyperandrogenic adolescents (age range, 14-22 yr; mean, 18.1 +/- 2.5 yr) 1) to determine FOH incidence through the assessment of ovarian-steroidogenic response to a single dose of leuprolide acetate, 2) to assess the clinical characteristics of patients according to their responses to GnRH analog stimulation, and 3) to evaluate adrenal steroidogenic function and its relation to ovarian hyperandrogenism in patients with either normal or abnormal responses to leuprolide acetate challenge. All patients underwent leuprolide acetate and ACTH testing, dexamethasone and ovarian suppression tests, and pelvic ultrasonography. Twenty-four (58%) patients had supranormal plasma 17-hydroxyprogesterone (17-OHP) responses to leuprolide acetate characteristic of FOH, and in 18, the 17-OHP response was similar to that of controls (n = 24; age, 17.1 +/- 2.3 yr). Seven patients (5 with FOH and 2 with normal responses to leuprolide acetate) had an abnormal response to ACTH, but only 1 had conclusive evidence of 21-hydroxylase deficiency. In 16 patients, the response to both stimulation tests was normal. Only 13 (54%) of the 24 FOH patients had polycystic ovaries on ultrasonography, and in 11 (46%), basal plasma LH levels were elevated. In FOH patients, reduction in testosterone and androstenedione plasma levels was significantly greater after ovarian suppression than after dexamethasone challenge (P < 0.0005 and P < 0.02, respectively). Peak plasma 17-OHP levels postleoprolide acetate simulation correlated with dexamethasone-suppressed plasma testosterone concentrations, dexamethasone-suppressed plasma androstenedione levels, and the free androgen index postdexamethasone treatment (r = 0.4, P = 0.01; r+ 0.4, P < 0.05; and r = 0.41, P = 0.007, respectively), Plasma sex hormone-binding globulin levels after dexamethasone administration correlated negatively with the baseline free androgen index (r = -.0.67; P < 0.0001). Considering our diagnostic criteria, 26 (62%) of our collective of 42 patients had abnormal responses to one or both stimulation tests, whereas 16 (37%) had normal response. FOH is the most common cause in (58%) of androgen excess in adolescence. Short term leuprolide acetate stimulation is a reliable tool fro identification of the ovary as the source of their hyperandrogenism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989484     DOI: 10.1210/jcem.79.6.7989484

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Contraception quandaries: oral contraceptive decisions in the pediatric endocrinology office.

Authors:  John S Fuqua; Emily K Sims
Journal:  J Clin Endocrinol Metab       Date:  2012-01       Impact factor: 5.958

2.  17-Hydroxyprogesterone responses to human chorionic gonadotropin are not associated with serum anti-Mullerian hormone levels among adolescent girls with polycystic ovary syndrome.

Authors:  Jingwen Hou; Heidi Cook-Andersen; H Irene Su; Rana Shayya; Kevin H Maas; Christine M Burt-Solorzano; Ajay Kumar; R Jeffrey Chang
Journal:  J Pediatr Endocrinol Metab       Date:  2016-07-01       Impact factor: 1.634

3.  Comparison between buserelin and dexamethasone testing in the assessment of hirsutism.

Authors:  T Re; L Barbetta; C Dall'Asta; G Faglia; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

4.  Value of buserelin testing in the evaluation of hirsute women.

Authors:  B Ambrosi; T Re; E Passini; D Bochicchio; R Ferrario
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

Review 5.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

6.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

Review 7.  Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset.

Authors:  L Ibáñez; F de Zegher; N Potau
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 8.  Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism.

Authors:  Lourdes Ibáñez; Rubén Díaz; Abel López-Bermejo; Maria Victoria Marcos
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

9.  Metabolic and hormonal assessment of adolescent and young adult women with prior premature adrenarche.

Authors:  Flávia Alves Ribeiro; Elisabete Aparecida Mantovani Rodrigues de Resende; Adriana Paula da Silva; Janaíne Machado Tomé; Heloísa Marcelina da Cunha Palhares; Maria de Fátima Borges
Journal:  Clinics (Sao Paulo)       Date:  2019-06-19       Impact factor: 2.365

10.  Increased Adrenal Androgens in Overweight Peripubertal Girls.

Authors:  Christine M Burt Solorzano; Kristin D Helm; James T Patrie; Rana F Shayya; Heidi L Cook-Andersen; R Jeffrey Chang; Christopher R McCartney; John C Marshall
Journal:  J Endocr Soc       Date:  2017-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.